Anti-malarial drugs
... (1)Anti-malarial action: It is an efficient schizontocide in erythrocytic stage, effective to chloroquineresistant subtertian malaria. (2)Clinical uses: ①to treat chloroquine-resistant subter-tian malaria. ②to prevent and control the symptoms of benign malaria, once/two week. (3)Adverse reaction: GI ...
... (1)Anti-malarial action: It is an efficient schizontocide in erythrocytic stage, effective to chloroquineresistant subtertian malaria. (2)Clinical uses: ①to treat chloroquine-resistant subter-tian malaria. ②to prevent and control the symptoms of benign malaria, once/two week. (3)Adverse reaction: GI ...
Drug Elimination and Clearance
... (ionized) drugs. Protein-bound drugs behave as large molecules and do not get filtered at the glomerulus. The major driving force for glomerular filtration is the hydrostatic pressure within the glomerular capillaries. The kidneys receive a large blood supply (approximately 25% of the cardiac output ...
... (ionized) drugs. Protein-bound drugs behave as large molecules and do not get filtered at the glomerulus. The major driving force for glomerular filtration is the hydrostatic pressure within the glomerular capillaries. The kidneys receive a large blood supply (approximately 25% of the cardiac output ...
Ditropan XL (sustained release oxybutynin)
... (91.9%) with a mean age of 59 years (range, 18 to 98 years). Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge) as evidenced by ≥ 6 urge incontinence episodes per week and ≥ 10 micturitions per day. Study 1 was a forced dose escalation design, whereas ...
... (91.9%) with a mean age of 59 years (range, 18 to 98 years). Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge) as evidenced by ≥ 6 urge incontinence episodes per week and ≥ 10 micturitions per day. Study 1 was a forced dose escalation design, whereas ...
alzheimer disease: treatment of noncognitive behavioral abnormalities
... generally well tolerated in these subjects. However, its cen tral anticholinergic effect likely accounted for subtle decre ments in cognitive function in the imipramine group. The improvement in HAM-D scores was similar to that achieved in the open inpatient studies reported by Greenwald et al. (2 ...
... generally well tolerated in these subjects. However, its cen tral anticholinergic effect likely accounted for subtle decre ments in cognitive function in the imipramine group. The improvement in HAM-D scores was similar to that achieved in the open inpatient studies reported by Greenwald et al. (2 ...
The Patented Medicines (Notice of Compliance) Regulations
... successful) in the issuance of a NOC to an applicant manufacturer by the Minister of Health on the advice of his officials in the Therapeutic Products Directorate. The FDA objective is to encourage bringing safe and effective medicines to market to advance the nation’s health. The achievement of thi ...
... successful) in the issuance of a NOC to an applicant manufacturer by the Minister of Health on the advice of his officials in the Therapeutic Products Directorate. The FDA objective is to encourage bringing safe and effective medicines to market to advance the nation’s health. The achievement of thi ...
Indocin - Iroko Pharmaceuticals
... Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk fo ...
... Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk fo ...
Herbal and Holistic Medicine in Latin America - TopSCHOLAR
... fatal, infections. Therefore, the need to alleviate the associated symptoms, if not to remove the cause completely, was introduced. In most cases, humans looked to nature for therapies, and often found them. At times, more physical remedies like acupuncture and trepanning were utilized. For other co ...
... fatal, infections. Therefore, the need to alleviate the associated symptoms, if not to remove the cause completely, was introduced. In most cases, humans looked to nature for therapies, and often found them. At times, more physical remedies like acupuncture and trepanning were utilized. For other co ...
This Article As A Word Document
... own children about it. Some think it is safer to use than alcohol. Many know individuals who have used marijuana either in the past or currently and who appear to be successful and have no apparent problems. What is a person to think? Is it really harmful? The following information will give you a p ...
... own children about it. Some think it is safer to use than alcohol. Many know individuals who have used marijuana either in the past or currently and who appear to be successful and have no apparent problems. What is a person to think? Is it really harmful? The following information will give you a p ...
rajiv gandhi university of health sciences
... Group C: Control group – 30 patients Before induction the patients of Group M will be pretreated with Inj. Magnesium sulfate 40 mg/kg body weight diluted to 20 ml with normal saline, while patients of Group C will be administered 20 ml of Normal saline intravenously over a period of 10 min. Patients ...
... Group C: Control group – 30 patients Before induction the patients of Group M will be pretreated with Inj. Magnesium sulfate 40 mg/kg body weight diluted to 20 ml with normal saline, while patients of Group C will be administered 20 ml of Normal saline intravenously over a period of 10 min. Patients ...
A Review on Fast Dissolving Sublingual Film
... 1. Student of M.pharm, department of Pharmaceuticeutical technology, L.J.Institute of Pharmacy, Ahmedabad, Gujarat, India 2. Assistant professor, Department of Pharmaceuticeutical technology, L.J.Institute of Pharmacy, Ahmedabad, Gujarat, India ...
... 1. Student of M.pharm, department of Pharmaceuticeutical technology, L.J.Institute of Pharmacy, Ahmedabad, Gujarat, India 2. Assistant professor, Department of Pharmaceuticeutical technology, L.J.Institute of Pharmacy, Ahmedabad, Gujarat, India ...
pain management guidelines - About PRC
... Peak effect of immediate-release opioid is ≈ one hour; may repeat dose every one hour if patient is not overly sedated. IV/SQ breakthrough dose is ≈ 50 to 100% of the hourly IV/SQ rate. Peak effect of IV opioids is ≈ 10-15 minutes; may repeat dose every 15 minutes if patient not overly sedated. Peak ...
... Peak effect of immediate-release opioid is ≈ one hour; may repeat dose every one hour if patient is not overly sedated. IV/SQ breakthrough dose is ≈ 50 to 100% of the hourly IV/SQ rate. Peak effect of IV opioids is ≈ 10-15 minutes; may repeat dose every 15 minutes if patient not overly sedated. Peak ...
Practical Pain Management - Idaho Quality of Life Coalition
... • Duragesic 50 mcg/hr = ~100 mg oral morphine per day ...
... • Duragesic 50 mcg/hr = ~100 mg oral morphine per day ...
Creatinine Clearance When Does It Matter?
... U.S. FDA. Center for Drug Evaluation and Research. Guidance for Industry: March 2010 Am J Kidney Dis. 2015; 65(2): 177-205 NKDEP. Chronic Kidney Disease nd Drug Dosing: Information for Providers. Jan. 2010 Kidney International 2011; 80: 1122-1137 ...
... U.S. FDA. Center for Drug Evaluation and Research. Guidance for Industry: March 2010 Am J Kidney Dis. 2015; 65(2): 177-205 NKDEP. Chronic Kidney Disease nd Drug Dosing: Information for Providers. Jan. 2010 Kidney International 2011; 80: 1122-1137 ...
Antimicrobial Agents
... Pneumocystis carinii in immunosuppressed patients. • Trimethoprim is increasingly used alone for urinary tract and upper respiratory tract infections, as it is less toxic than the combination and equally effective. ...
... Pneumocystis carinii in immunosuppressed patients. • Trimethoprim is increasingly used alone for urinary tract and upper respiratory tract infections, as it is less toxic than the combination and equally effective. ...
Stilnox - Sanofi
... Next-day residual effects: There was no evidence of residual next-day effects seen with STILNOX in several studies utilising the Multiple Sleep Latency Test (MSLT), the Digit Symbol Substitution Test (DSST), and patient ratings of alertness. In one study involving elderly patients, there was a small ...
... Next-day residual effects: There was no evidence of residual next-day effects seen with STILNOX in several studies utilising the Multiple Sleep Latency Test (MSLT), the Digit Symbol Substitution Test (DSST), and patient ratings of alertness. In one study involving elderly patients, there was a small ...
Module 3. Pharmaceutical care during OTC medications vacation
... 77. Patient teaching regarding sublingual nitroglycerin should include which of the following statements: A. "You can take up to five doses every 3 minutes for chest pain." ...
... 77. Patient teaching regarding sublingual nitroglycerin should include which of the following statements: A. "You can take up to five doses every 3 minutes for chest pain." ...
American College of Rheumatology
... Highlights of the American College of Rheumatology 2010 Scientific Meeting It might sound a bit odd, but what ALR Scientific Advisory Board Chair Mary (Peggy) K. Crow, MD found most interesting from this year’s meeting had to do with rheumatoid arthritis (RA). Specifically, the possibility that bac ...
... Highlights of the American College of Rheumatology 2010 Scientific Meeting It might sound a bit odd, but what ALR Scientific Advisory Board Chair Mary (Peggy) K. Crow, MD found most interesting from this year’s meeting had to do with rheumatoid arthritis (RA). Specifically, the possibility that bac ...
In Pursuit of Science-based Regulation: FDA, FTC, and the
... failure.22 St. John’s Wort—commonly used as an over-the-counter antidepressant—can interact dangerously with other antidepressants, and other drugs. 23 And since most patients don’t tell their physicians about their supplement use, dangerous interactions and effects can go undiagnosed, and untreated ...
... failure.22 St. John’s Wort—commonly used as an over-the-counter antidepressant—can interact dangerously with other antidepressants, and other drugs. 23 And since most patients don’t tell their physicians about their supplement use, dangerous interactions and effects can go undiagnosed, and untreated ...
ppt - Chair of Computational Biology
... Evaluating QSAR equations (I) The most important statistical measures to evaluate QSAR equations are: Correlation coefficient r (squared as r2 > 0.75) Standard deviation se (small as possible, se < 0.4 units) Fisher value F (level of statistical significance. Also a measure for the portability of t ...
... Evaluating QSAR equations (I) The most important statistical measures to evaluate QSAR equations are: Correlation coefficient r (squared as r2 > 0.75) Standard deviation se (small as possible, se < 0.4 units) Fisher value F (level of statistical significance. Also a measure for the portability of t ...
Effectiveness of oral ivermectin for eradicating infesting mites in
... single dose of ivermectin and did not show any mite during follow-up period. This result is similar to what has previously been reported by Brooks and Grace in 2002.8 They observed a cure rate of 56% after a single dose of ivermectin. The authors described cure as absence of skin lesions in patients ...
... single dose of ivermectin and did not show any mite during follow-up period. This result is similar to what has previously been reported by Brooks and Grace in 2002.8 They observed a cure rate of 56% after a single dose of ivermectin. The authors described cure as absence of skin lesions in patients ...
Comparison of a 3‐day with a 1‐day regimen of an extended
... the difference was not statistically significant. In this population, the clinical response at the final visit was 98.5% and 96.7% for patients receiving the 3-day and the 1-day regimens, respectively (95% CI −5.2%, 0.8%). However, in the clinical efficacy population the clinical success rate was si ...
... the difference was not statistically significant. In this population, the clinical response at the final visit was 98.5% and 96.7% for patients receiving the 3-day and the 1-day regimens, respectively (95% CI −5.2%, 0.8%). However, in the clinical efficacy population the clinical success rate was si ...
Barnsley Area Prescribing Committee
... Monitoring of prolactin levels will be done according to clinical requirements and dose adjusted as required A baseline ECHO will be performed at initiation of therapy with any clinical issues highlighted being used to determine further monitoring and use Monitoring for signs of pituitary enlargemen ...
... Monitoring of prolactin levels will be done according to clinical requirements and dose adjusted as required A baseline ECHO will be performed at initiation of therapy with any clinical issues highlighted being used to determine further monitoring and use Monitoring for signs of pituitary enlargemen ...
Opioid Dosing and Conversions
... fentanyl. Example: patients with diffuse edema or cachexia have lower than anticipated fentanyl absorption. External heat increases absorption from fentanyl patches. Author(s): Hartman, Gustin; Department: Pharmacy; Date Originated: May 2009; Committee(s) Approved: P&T/MUE Executive Committee This i ...
... fentanyl. Example: patients with diffuse edema or cachexia have lower than anticipated fentanyl absorption. External heat increases absorption from fentanyl patches. Author(s): Hartman, Gustin; Department: Pharmacy; Date Originated: May 2009; Committee(s) Approved: P&T/MUE Executive Committee This i ...
SENIOR: Solifenacin (VESICARE) vs Oxybutynin
... At first glance this trial appears to support the use of solifenacin over oxybutynin because of their differing effects on cognition in elderly people with MCI. However, this is somewhat misleading as there was no difference in the primary end‐point studied. There is some potential for differences ...
... At first glance this trial appears to support the use of solifenacin over oxybutynin because of their differing effects on cognition in elderly people with MCI. However, this is somewhat misleading as there was no difference in the primary end‐point studied. There is some potential for differences ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.